Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed133%
withdrawn133%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruiting

Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder

NCT05529901
completednot_applicable

Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

NCT01711983
withdrawnnot_applicable

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

NCT03232450

Clinical Trials (3)

Showing 3 of 3 trials
NCT05529901

Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder

Active Not Recruiting
NCT01711983Not Applicable

Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

Completed
NCT03232450Not Applicable

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3